Autoimmune demyelinating disease
Not yet recruitingEfficacy of efgartigimod alfa as first‑line add‑on to IV methylprednisolone for moderate‑to‑severe attacks in patients with demyelinating diseases
Efficacy of efgartigimod alfa as first‑line add‑on to IV methylprednisolone for moderate‑to‑severe attacks in patients with demyelinating diseases
- Disease:Autoimmune demyelinating disease
- Substances:Efgartigimod Alfa
Germany- Participants:18–64 years · 65+ years
- Substances:Efgartigimod Alfa
- Sponsor:Medizinische Hochschule Hannover








